Categories Earnings, Retail

Budweiser, Corona to drive Anheuser Busch InBev Q3 earnings

Brewing giant Anheuser Busch InBev (NYSE:BUD) will report third-quarter financial results before the market hours on Friday, October 25. Analysts expect the Budweiser-parent to report a year-over-year increase in earnings and revenues in Q3.

Even as overall beer demand remains soft, popular brands such as Budweiser and Corona continue to see strength. Also, strength in the international markets is likely to offset any weakness in US sales. During the third quarter, total revenue is projected to increase 4% to $13.82 billion.

CREDIT: Blake Guidry/Unsplash

There has been a change in consumer preferences towards healthier drinks, primarily in the US, hurting sales of soda and beer. Anheuser Busch was forced to buy up numerous craft brewers over the past few years to maintain its market position in the beer industry.

Down the line, the Belgian firm is expected to report earnings of $1.16 per share, compared to 82 cents per share a year ago. In the trailing four quarters, Anheuser Busch has exceed market consensus on earnings on two occasions.

READ: McDonald’s misses Q3 earnings target by 10 cents

During the last-reported quarter, the company reported better-than-expected revenues and income, sending the stock higher.

Meanwhile, better revenues and income may not, in itself, satiate the thirst of investors. The market will also be looking at the brewer’s balance sheet, which is not among its strong points. Post the SAB Miller acquisition last year, the company had incurred significant debts, which later forced it to slash its dividends. Investors will need more clarity on the advantages of holding on to a stock with unstable dividends.

BUD shares have increased 38% in the year-to-date period. It’s 12-month average price target of $103.67 is at a 13% upside from Wednesday’s trading price.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top